Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 17/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854528 | 0.92 | CTSC (0.49) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854506 | 0.89 | WEE1 (0.51) | JAK2JAK3BRD4MARK3MARK4 | |
| SCHEMBL12854527 | 0.86 | JAK2 (0.52) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854526 | 0.86 | JAK2 (0.53) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL14481862 | 0.86 | BRD4 (0.55) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854511 | 0.83 | JAK2 (0.57) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854518 | 0.83 | JAK2 (0.53) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854531 | 0.82 | JAK2 (0.53) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854522 | 0.81 | BRD4 (0.52) | JAK2JAK1JAK3BRD4CTSC | |
| SCHEMBL12854379 | 0.80 | JAK1 (0.56) | JAK2JAK1JAK3BRD4CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK2 854/4885JAK1 567/4885JAK3 1186/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK2 994/4885JAK1 503/4885JAK3 1030/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK2 854/4885JAK1 567/4885JAK3 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.